BeOne Medicines Ltd. (formerly BeiGene) is a global oncology company focused on developing and commercializing innovative medicines for cancer patients. The company develops both small molecule and large molecule biologic therapies, operates its own manufacturing facilities, and markets approved medicines across the U.S., China, EU, UK, Switzerland, and other international markets. It also engages in strategic collaborations and licensing arrangements to expand its pipeline.
expected 2026-11-25
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | ONC | discussed Regulation | Q4 FY2025 |
| topic_mention | ONC | discussed Automotive | Q4 FY2025 |
| topic_mention | ONC | discussed Healthcare & Bio | Q4 FY2025 |
| guidance | ONC | guided guidance of $6.2 billion | Q4 FY2025 |
| guidance | ONC | guided guidance for full year 2026 of $6.2 billion | Q4 FY2025 |
| guidance | ONC | guided guidance on items impacting net income and earnings per ADS: • Other income (expense) : estimated range of $25 million | Q4 FY2025 |
| topic_mention | ONC | discussed Artificial Intelligence | |
| topic_mention | ONC | discussed Blockchain & Crypto | |
| topic_mention | ONC | discussed Networking | |
| topic_mention | ONC | discussed Regulation | |
| topic_mention | ONC | discussed Automotive | |
| topic_mention | ONC | discussed Healthcare & Bio | |
| metric | ONC free cash flow | reported $380 million | |
| guidance | ONC | guided expected to be between $700 and $800 million | |
| guidance | ONC | guided expect expenses to be between $25 to $50 million | |
| outlook | ONC | stated we believe that true innovation comes from improving upon the best | |
| outlook | ONC | stated We believe BeOne is the only company with the foundational assets in our CLL portfolio and pipeline to take us there | |
| outlook | ONC | stated we believe ZS is that therapy | |
| outlook | ONC | stated We expect another strong year of revenue growth with continued global leadership for BRUKINSA | |
| outlook | ONC | stated We anticipate that the U |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-011946 | EDGAR | 136K words |
| 2025-02-27 | 2024-12-31 | 0001651308-25-000031 | EDGAR | 124K words |
| 2024-02-26 | 2023-12-31 | 0001651308-24-000014 | EDGAR | 133K words |
| 2023-02-27 | 2022-12-31 | 0001651308-23-000036 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001651308-22-000032 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001651308-21-000039 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001651308-20-000020 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001651308-19-000018 | EDGAR | — |
| 2018-02-28 | 2017-12-31 | 0001558370-18-001303 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001628280-26-052878 | EDGAR | 74K words |
| 2026-05-06 | 2026-03-31 | 0001628280-26-030867 | EDGAR | 70K words |
| 2025-11-06 | 2025-09-30 | 0001628280-25-049824 | EDGAR | 71K words |
| 2025-08-06 | 2025-06-30 | 0001651308-25-000133 | EDGAR | 70K words |
| 2025-05-07 | 2025-03-31 | 0001651308-25-000075 | EDGAR | 65K words |
| 2024-11-12 | 2024-09-30 | 0001651308-24-000152 | EDGAR | 67K words |
| 2024-08-07 | 2024-06-30 | 0001651308-24-000098 | EDGAR | 67K words |
| 2024-05-08 | 2024-03-31 | 0001651308-24-000051 | EDGAR | 64K words |
| 2023-11-09 | 2023-09-30 | 0001651308-23-000165 | EDGAR | 86K words |
| 2023-08-02 | 2023-06-30 | 0001651308-23-000127 | EDGAR | 91K words |
| 2023-05-04 | 2023-03-31 | 0001651308-23-000068 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001651308-22-000209 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-26 | 0001651308-26-000025 | EDGAR | 1K words |
| 2026-08-05 | 0001628280-26-052877 | EDGAR | 8K words |
| 2026-06-26 | 0001651308-26-000020 | EDGAR | 1K words |
| 2026-06-11 | 0001651308-26-000017 | EDGAR | 3K words |
| 2026-05-15 | 0001651308-26-000012 | EDGAR | 2K words |
| 2026-05-06 | 0001628280-26-030866 | EDGAR | 6K words |
| 2026-04-14 | 0001651308-26-000008 | EDGAR | 1K words |
| 2026-02-26 | 0001628280-26-011941 | EDGAR | 8K words |
| 2025-12-19 | 0001651308-25-000153 | EDGAR | 1K words |
| 2025-12-18 | 0001651308-25-000151 | EDGAR | 1K words |
311 total filings indexed. 280 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| Call Date | Quarter | Title |
|---|---|---|
| — | Q4 FY2025 | ONC Q4 FY2025 Earnings Call Transcript |
| — | ONC Earnings Call Transcript |
Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.
| CIK | 0001651308 |
| Ticker | ONC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.beonemedicines.com |
| Listed | 2016-02-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ONC (~200 tokens, structured JSON with cryptographic provenance)